Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
about
Rodent models of focal stroke: size, mechanism, and purposeSynergy of combined tPA-edaravone therapy in experimental thrombotic strokeIn Situ Microparticles Loaded with S-Nitrosoglutathione Protect from Stroke.Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.Experimental models of brain ischemia: a review of techniques, magnetic resonance imaging, and investigational cell-based therapies.Present status of magnetic resonance imaging and spectroscopy in animal stroke models.Characterization of a new model of thromboembolic stroke in C57 black/6J miceDifferent strokes for different folks: the rich diversity of animal models of focal cerebral ischemiaComparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.Animal models of stroke: translational potential at present and in 2050High CD3+ Cells in Intracranial Thrombi Represent a Biomarker of Atherothrombotic Stroke.Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion modelSpontaneous thrombolysis: a forgotten determinant of life or death.Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats.Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemiaProtective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke.Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation.Factors affecting clinical outcome in large-vessel occlusive ischemic strokes.Animal models of ischemic stroke and their application in clinical researchClot injection technique affects thrombolytic efficacy in a rat embolic stroke model: implications for translaboratory collaborations.Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.Embolic middle cerebral artery occlusion model using thrombin and fibrinogen composed clots in rat.A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia.The Importance of Considering Sex Differences in Translational Stroke Research.Relationship between thrombus attenuation and different stroke subtypes.Control of cerebral ischemia with magnetic nanoparticles.Role of Hyperintense Acute Reperfusion Marker for Classifying the Stroke Etiology.Is shorter transient middle cerebral artery occlusion (t-MCAO) duration better in stroke experiments on diabetic female Sprague Dawely rats?Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.Calcification and endothelialization of thrombi in acute stroke.
P2860
Q24529165-E2AEDC15-C8C0-47E8-9937-84AD94F2D2AFQ28539510-A1616F3F-2D1D-4F9F-8514-8F5471F30D18Q30395928-D9FD66CF-E682-4409-AE08-2CE25298760FQ30492023-89272570-B8EF-4B29-830F-4DAAD0017A0DQ30771799-F096DB37-E43D-496D-A32D-54561F587C3DQ33227334-5EBB04F8-72AD-41EB-BA12-3B264F4EC873Q33883140-5A705417-E706-4243-BD4B-46CCA6D9EFD0Q34171291-2A9DFF0C-63B9-4F29-8D6C-C3854AA32138Q34207727-7649D979-F814-4280-90CF-8A9E2362A958Q34700931-E0E1E539-6DF9-453A-ACD6-E5806A77CD5EQ36010610-6FA1D069-0A71-4C1B-862B-E15D2AAAF0C7Q36237842-FCB28BEA-9B82-4C66-91D7-C3F45C8D5EFEQ36588653-6AF61808-F06B-4A1D-8426-048E50CCE127Q36856265-AA8FD221-2137-4725-8450-975FC5C9A735Q36917102-6A53112D-D01C-4A64-8F27-EDF7A69F1470Q37230709-F9A0B8BB-717E-4932-8DA8-4E6D948CE199Q37347802-5C124E36-5727-41CC-923C-DAC24FCA369CQ37578017-E4E9C5B8-FC97-43F6-8910-B2DFC61016CBQ38282646-E83AAD61-A25E-474A-82C8-A5662099BCABQ38546471-26D75B3E-65BC-4FCA-9EC6-84D9609D9459Q38688253-5B684192-3BF2-48BC-96AD-6FECD1CF91A8Q40754685-9382510D-BF31-442E-B42F-964FA3991106Q41437445-B7C485FA-B903-42DB-B215-90BA3BF4AF53Q41866520-1049B539-C4FF-40F3-B411-4053329826FCQ42085888-67CA57A4-BBCA-41BA-BCA4-D6750A09A17DQ45276392-5ECB266E-EFF7-42FC-BD1F-34EB526D472BQ46620582-55EBA946-9013-4CA9-8E39-0357325BE706Q47099634-738A0990-914A-4597-9296-12AD739A65AAQ48020232-F828AB12-D2FC-4BBE-BE53-C934D4D3E2E4Q48593375-50F4E6BB-A2F8-4250-BC76-B8B5DE64E41FQ50644973-EF7848AF-C321-48C8-84E8-3358C2F29DB3
P2860
Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Differences in clot preparatio ...... imental thromboembolic stroke.
@en
Differences in clot preparatio ...... imental thromboembolic stroke.
@nl
type
label
Differences in clot preparatio ...... imental thromboembolic stroke.
@en
Differences in clot preparatio ...... imental thromboembolic stroke.
@nl
prefLabel
Differences in clot preparatio ...... imental thromboembolic stroke.
@en
Differences in clot preparatio ...... imental thromboembolic stroke.
@nl
P2093
P1433
P1476
Differences in clot preparatio ...... imental thromboembolic stroke.
@en
P2093
Frank Niessen
Konstantin-A Hossmann
Thomas Hilger
P304
P356
10.1161/01.STR.0000080941.73934.30
P407
P577
2003-07-03T00:00:00Z